Facebook
Twitter
Telegram
Report an ErrorLigand Pharmaceuticals Incorporated Financial Ratios 2011-2024 | LGND
Annual Financial Ratios Ligand Pharmaceuticals Incorporated
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
26.0 | -36.4 | 36.3 | -1005.0 | 2.7 | 17.4 | 276.2 | -1287.8 | 7.7 | 96.7 | 111.9 | -752.7 | 23.7 |
P/S |
10.3 | 6.2 | 8.6 | 18.3 | 14.2 | 9.9 | 24.6 | 19.3 | 27.5 | 18.0 | 26.1 | 12.6 | 8.0 |
EPS |
3.0 | -2.0 | 3.4 | -0.2 | 33.1 | 6.8 | 0.6 | -0.1 | 11.6 | 0.6 | 0.6 | -0.0 | 0.5 |
EV (Enterprise Value) |
1.42 B | 1.33 B | 2.53 B | 3.6 B | 2.36 B | 3.07 B | 3.72 B | 2.35 B | 2.11 B | 1.24 B | 1.32 B | 462 M | 348 M |
EBITDA per Share |
2.8 | 3.24 | 9.32 | 3.9 | 0.587 | 8.48 | 3.81 | 2.67 | 1.57 | 1.14 | 0.918 | 0.182 | 0.135 |
EV/EBITDA |
19.4 | 105.7 | 204.0 | 16.8 | 46.0 | 41.9 | 67.4 | 51.3 | 68.4 | 114.1 | 98.3 | ||
PEG |
0.24 | -0.27 | 0.23 | -7.1 | 0.01 | 0.02 | -0.32 | 12.8 | 0.0 | 18.04 | -0.06 | 7.12 | -0.13 |
P/B |
1.9 | 2.0 | 2.5 | 4.2 | 2.2 | 4.4 | 8.7 | 6.2 | 6.5 | 47.6 | 25.8 | 15.0 | 27.9 |
P/CF |
27.4 | 8.8 | 26.3 | 55.0 | -53.5 | 13.7 | 40.1 | 60.8 | 64.1 | 72.3 | 81.1 | -46.8 | -192.9 |
ROE % |
7.44 | -5.58 | 6.96 | -0.42 | 82.02 | 25.55 | 3.14 | -0.48 | 84.53 | 49.26 | 23.02 | -1.99 | 117.70 |
ROA % |
6.63 | -4.37 | 4.40 | -0.22 | 42.10 | 11.37 | 1.87 | -0.27 | 48.19 | 4.66 | 10.91 | -0.51 | 8.32 |
ROCE % |
1.70 | 0.51 | 12.65 | 5.29 | -0.39 | 13.89 | 15.75 | 12.00 | 5.53 | 8.80 | 21.09 | 1.29 | -0.18 |
Current Ratio |
9.1 | 4.6 | 2.7 | 2.1 | 66.1 | 10.6 | 1.0 | 0.7 | 10.3 | 8.1 | 0.9 | 0.7 | 0.7 |
DSO |
88.0 | 107.8 | 107.5 | 97.3 | 126.7 | 81.1 | 77.5 | 61.0 | 59.3 | 77.1 | 50.1 | 104.0 | 149.6 |
DIO |
- | - | - | - | 234.7 | 410.3 | 297.5 | 126.0 | 102.6 | 10.7 | 88.6 | 172.0 | 96.7 |
DPO |
- | - | - | - | 77.8 | 240.9 | 153.7 | 179.1 | 256.6 | 307.5 | 251.6 | 593.4 | 822.7 |
Operating Cycle |
88.0 | 107.8 | 107.5 | 97.3 | 361.4 | 491.4 | 375.0 | 187.0 | 161.9 | 87.9 | 138.8 | 276.0 | 246.3 |
Cash Conversion Cycle |
88.0 | 107.8 | 107.5 | 97.3 | 283.5 | 250.5 | 221.3 | 7.9 | -94.7 | -219.7 | -112.8 | -317.4 | -576.4 |
All numbers in USD currency
Quarterly Financial Ratios Ligand Pharmaceuticals Incorporated
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
4.86 | - | -0.59 | 0.13 | 2.46 | - | 0.02 | -0.05 | -0.91 | - | 0.82 | 1.84 | 1.1 | 0.36 | -0.42 | 1.38 | -1.46 | -0.43 | -0.81 | -0.74 | 32.59 | -2.02 | 3.19 | 3.45 | 2.13 | -2.02 | 3.19 | 3.45 | 2.13 | 0.15 | 0.05 | -0.3 | 0.32 | 0.32 | 10.01 | 1.19 | 0.04 | 0.35 | 0.06 | 0.08 | 0.1 | 0.09 | 0.1 | 0.3 | 0.07 | 0.05 | -0.01 | -0.13 | 0.06 | 0.24 | -0.21 | -0.02 | 0.49 |
EBITDA per Share |
0.66 | - | - | - | 1.39 | - | 3.12 | 2.11 | 0.94 | - | 3.21 | 4.26 | 1.05 | - | 1.02 | 0.93 | 0.44 | - | 0.35 | 0.18 | 40.6 | - | 1.64 | 3.59 | 1.89 | - | 1.14 | 0.88 | 0.62 | - | 0.66 | 0.45 | 0.85 | - | 0.46 | 0.25 | 0.2 | - | 0.21 | 0.1 | 0.28 | - | 0.18 | 0.11 | 0.23 | - | - | - | - | - | -0.13 | 0.03 | -0.05 |
ROE % |
7.95 | 5.30 | 5.35 | 6.93 | 6.48 | -2.00 | -0.31 | 1.33 | 5.35 | 8.02 | 8.84 | 6.20 | 5.41 | -0.42 | -2.19 | -3.24 | -8.23 | 82.02 | 75.41 | 89.41 | 104.33 | 25.55 | 22.50 | 27.34 | 32.60 | 35.85 | 45.56 | 29.02 | 8.91 | -0.48 | 3.11 | 86.74 | 98.48 | 96.86 | 120.99 | 41.92 | 38.04 | 45.69 | 22.65 | 21.74 | 27.97 | 23.02 | 23.26 | 18.57 | -3.25 | -1.99 | 51.30 | 0.98 | 5.38 | 57.30 | -51.04 | -5.16 | - |
ROA % |
7.06 | 4.14 | 4.18 | 5.55 | 5.17 | -1.44 | -0.36 | 0.68 | 3.21 | 4.92 | 5.34 | 3.77 | 2.95 | -0.22 | -1.13 | -1.66 | -4.25 | 42.10 | 39.22 | 45.58 | 52.35 | 11.37 | 8.41 | 13.10 | 18.20 | 21.36 | 27.17 | 17.31 | 5.38 | -0.27 | 1.51 | 40.92 | 46.63 | 45.69 | 47.16 | 8.06 | 4.00 | 4.66 | 3.71 | 5.09 | 10.29 | 10.91 | 10.14 | 8.08 | -0.16 | -0.51 | 2.36 | -0.91 | 1.16 | 8.06 | -3.46 | -0.35 | 7.98 |
ROCE % |
0.99 | 2.36 | 3.87 | 4.92 | 6.30 | 2.86 | 4.79 | 5.22 | 9.95 | 8.38 | 8.91 | 7.50 | 2.69 | 2.06 | 1.39 | 0.19 | -1.35 | 106.52 | 110.68 | 115.52 | 128.57 | 23.28 | 27.40 | 27.37 | 18.11 | 9.94 | 11.54 | 9.01 | 6.92 | 7.19 | 10.81 | 12.83 | 13.51 | 6.87 | 20.29 | 30.09 | 33.41 | 37.96 | 44.15 | 36.91 | 34.81 | 17.16 | 11.78 | 0.22 | -9.69 | -15.40 | -55.10 | -89.41 | -92.45 | - | -39.69 | -9.90 | - |
Current Ratio |
8.5 | 9.1 | 7.6 | 8.1 | 4.9 | 4.6 | 4.5 | 3.9 | 3.5 | 2.7 | 2.8 | 2.7 | 2.4 | 2.1 | 2.1 | 2.1 | 2.1 | 2.0 | 2.0 | 2.0 | 2.0 | 1.8 | 1.8 | 1.8 | 1.8 | 2.7 | 2.7 | 2.7 | 2.7 | 2.6 | 2.6 | 2.6 | 2.6 | 2.2 | 2.2 | 2.2 | 2.2 | 1.1 | 1.1 | 1.1 | 1.1 | 1.9 | 1.9 | 1.9 | 1.9 | 1.3 | 1.3 | 1.3 | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 |
DSO |
90.4 | - | 88.8 | 99.0 | 61.8 | - | 98.2 | 94.8 | 159.0 | - | 86.2 | 60.7 | 92.1 | 74.1 | 124.0 | 125.2 | 120.0 | 88.4 | 77.6 | 85.6 | 86.5 | 78.7 | 102.7 | 56.6 | 66.2 | 46.3 | 70.0 | 83.4 | 62.8 | 35.1 | 62.0 | 68.7 | 32.1 | 26.6 | 31.8 | 30.6 | 58.8 | 50.1 | 77.0 | 108.7 | 42.5 | 13.8 | 15.6 | 21.2 | 26.7 | 30.7 | 65.7 | 72.9 | 86.6 | 43.1 | 97.1 | 74.7 | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 211.6 | 276.8 | 170.5 | - | 445.2 | 573.2 | 665.7 | - | 167.3 | 441.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 70.2 | 91.8 | 78.1 | - | 261.4 | 336.6 | 373.0 | - | 86.4 | 228.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
90.4 | - | 88.8 | 99.0 | 61.8 | - | 98.2 | 94.8 | 159.0 | - | 86.2 | 60.7 | 92.1 | 74.1 | 124.0 | 125.2 | 120.0 | 88.4 | 289.2 | 362.4 | 257.1 | 78.7 | 548.0 | 629.9 | 731.8 | 46.3 | 237.3 | 525.3 | 62.8 | 35.1 | 62.0 | 68.7 | 32.1 | 26.6 | 31.8 | 30.6 | 58.8 | 50.1 | 77.0 | 108.7 | 42.5 | 13.8 | 15.6 | 21.2 | 26.7 | 30.7 | 65.7 | 72.9 | 86.6 | 43.1 | 97.1 | 74.7 | - |
Cash Conversion Cycle |
90.4 | - | 88.8 | 99.0 | 61.8 | - | 98.2 | 94.8 | 159.0 | - | 86.2 | 60.7 | 92.1 | 74.1 | 124.0 | 125.2 | 120.0 | 88.4 | 219.0 | 270.6 | 179.0 | 78.7 | 286.6 | 293.2 | 358.9 | 46.3 | 150.9 | 297.1 | 62.8 | 35.1 | 62.0 | 68.7 | 32.1 | 26.6 | 31.8 | 30.6 | 58.8 | 50.1 | 77.0 | 108.7 | 42.5 | 13.8 | 15.6 | 21.2 | 26.7 | 30.7 | 65.7 | 72.9 | 86.6 | 43.1 | 97.1 | 74.7 | - |
All numbers in USD currency